Vitamin D for the prevention of cardiovascular disease: Are we ready for that?

Atherosclerosis

Volumn 241, Issue 2, 2015, Pages 729-740

  Carvalho, Luiz Sergio F ^a,b   Sposito, Andrei C ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b HOSPITAL DE BASE DO DISTRITO FEDERAL   (Brazil)

Author keywords

Atherosclerosis; Cardiovascular risk; Endothelial function; Vitamin D

Indexed keywords

GLUCOSE; INSULIN; PARATHYROID HORMONE; VITAMIN D;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BARIATRIC SURGERY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENDOTHELIUM CELL; FIBRINOLYSIS; GLUCOSE HOMEOSTASIS; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INTERVENTION STUDY; LIPID METABOLISM; PRIORITY JOURNAL; REVIEW; VASODILATATION; VITAMIN SUPPLEMENTATION; ANIMAL; ARRHYTHMIAS, CARDIAC; BLOOD; CARDIAC MUSCLE; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENT; HYPERTROPHY; INFLAMMATION; LONGITUDINAL STUDY; METABOLISM; METHODOLOGY; PATHOLOGY; RISK; VITAMIN D DEFICIENCY;

ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; HUMANS; HYPERTENSION; HYPERTROPHY; INFLAMMATION; LIPID METABOLISM; LONGITUDINAL STUDIES; MYOCARDIUM; PARATHYROID HORMONE; RESEARCH DESIGN; RISK; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84933558093     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.06.034     Document Type: Review

References (95)

1. Ridker P.M., Genest J., Boekholdt S.M., Libby P., Gotto A.M., Nordestgaard B.G., Mora S., MacFadyen J.G., Glynn R.J., Kastelein J.J. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the Jupiter trial. Lancet 2010, 376:333-339.
2. Fruchart J.C., Sacks F.M., Hermans M.P., Assmann G., Brown W.V., Ceska R., Chapman M.J., Dodson P.M., Fioretto P., Ginsberg H.N., Kadowaki T., Lablanche J.M., Marx N., Plutzky J., Reiner Z., Rosenson R.S., Staels B., Stock J.K., Sy R., Wanner C., Zambon A., Zimmet P. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc. Dis. Res. 2008, 5:319-335.
3. Myung S.K., Ju W., Cho B., Oh S.W., Park S.M., Koo B.K., Park B.J., Korean Meta-Analysis Study Group Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. Bmj 2013, 346:f10.
4. Euromonitor Vitamins and Dietary Supplements in the US 2013, 65. Euromonitor Consumer Health Database, Euromonitor. April, 2013 ed.
5. Somjen D., Weisman Y., Kohen F., Gayer B., Limor R., Sharon O., Jaccard N., Knoll E., Stern N. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005, 111:1666-1671.
6. Chen S., Glenn D.J., Ni W., Grigsby C.L., Olsen K., Nishimoto M., Law C.S., Gardner D.G. Expression of the vitamin d receptor is increased in the hypertrophic heart. Hypertension 2008, 52:1106-1112.
7. Borges A.C., Feres T., Vianna L.M., Paiva T.B. Effect of cholecalciferol treatment on the relaxant responses of spontaneously hypertensive rat arteries to acetylcholine. Hypertension 1999, 34:897-901.
8. Uberti F., Lattuada D., Morsanuto V., Nava U., Bolis G., Vacca G., Squarzanti D.F., Cisari C., Molinari C. Vitamin D protects human endothelial cells from oxidative stress through the autophagic and survival pathways. J.Clin. Endocrinol. Metab. 2014, 99(4):1367-1374.
9. Polidoro L., Properzi G., Marampon F., Gravina G.L., Festuccia C., Di Cesare E., Scarsella L., Ciccarelli C., Zani B.M., Ferri C. Vitamin D protects human endothelial cells from H(2)O(2) oxidant injury through the Mek/Erk-Sirt1 axis activation. J.Cardiovasc. Transl. Res. 2013, 6:221-231.
10. Andrukhova O., Slavic S., Zeitz U., Riesen S.C., Heppelmann M.S., Ambrisko T.D., Markovic M., Kuebler W.M., Erben R.G. Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice. Mol. Endocrinol. 2014, 28(1):53-64.
11. Wong M.S., Delansorne R., Man R.Y., Svenningsen P., Vanhoutte P.M. Chronic treatment with vitamin D lowers arterial blood pressure and reduces endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am. J. Physiol. Heart Circ Physiol 2010, 299:H1226-H1234.
12. Wong M.S., Man R.Y., Vanhoutte P.M. Calcium-independent phospholipase A(2) plays a key role in the endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H1260-H1266.
13. Hirata M., Serizawa K., Aizawa K., Yogo K., Tashiro Y., Takeda S., Moriguchi Y., Endo K., Fukagawa M. 22-Oxacalcitriol prevents progression of endothelial dysfunction through antioxidative effects in rats with type 2 diabetes and early-stage nephropathy. Nephrol. Dial. Transplant. 2013, 28(5):1166-1174.
14. Guarente L., Franklin H. Epstein Lecture: sirtuins, aging, and medicine. N.Engl. J. Med. 2011, 364:2235-2244.
15. Stein S., Matter C.M. Protective roles of SIRT1 in atherosclerosis. Cell. cycle 2011, 10:640-647.
16. Jablonski K.L., Chonchol M., Pierce G.L., Walker A.E., Seals D.R. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension 2011, 57:63-69.
17. Sugden J.A., Davies J.I., Witham M.D., Morris A.D., Struthers A.D. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet. Med. J. Br. Diabet. Assoc. 2008, 25:320-325.
18. Yiu Y.F., Yiu K.H., Siu C.W., Chan Y.H., Li S.W., Wong L.Y., Lee S.W., Tam S., Wong E.W., Lau C.P., Cheung B.M., Tse H.F. Randomized controlled trial of vitamin D supplement on endothelial function in patients with type 2 diabetes. Atherosclerosis 2013, 227:140-146.
19. Sokol S.I., Srinivas V., Crandall J.P., Kim M., Tellides G., Lebastchi A.H., Yu Y., Gupta A.K., Alderman M.H. The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease. Vasc. Med. 2012, 17:394-404.
20. Talmor Y., Bernheim J., Klein O., Green J., Rashid G. Calcitriol blunts pro-atherosclerotic parameters through NFkappaB and p38 invitro. Eur. J. Clin. Invest. 2008, 38:548-554.
21. Kudo K., Hasegawa S., Suzuki Y., Hirano R., Wakiguchi H., Kittaka S., Ichiyama T. 1alpha,25-dihydroxyvitamin D(3) inhibits vascular cellular adhesion molecule-1 expression and interleukin-8 production in human coronary arterial endothelial cells. J.Steroid Biochem. Mol. Biol. 2012, 132:290-294.
22. Albert P.J., Proal A.D., Marshall T.G. Vitamin D: the alternative hypothesis. Autoimmun. Rev. 2009, 8:639-644.
23. Welsh J. Targets of vitamin D receptor signaling in the mammary gland. J.Bone Mineral Res. Off. J. Am. Soc. Bone Mineral Res. 2007, 22(Suppl.2):V86-V90.
24. Proal A.D., Albert P.J., Marshall T.G. Dysregulation of the vitamin D nuclear receptor may contribute to the higher prevalence of some autoimmune diseases in women. Ann. N. Y. Acad. Sci. 2009, 1173:252-259.
25. Schleithoff S.S., Zittermann A., Tenderich G., Berthold H.K., Stehle P., Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 2006, 83:754-759.
26. Das M., Tomar N., Sreenivas V., Gupta N., Goswami R. Effect of vitamin D supplementation on cathelicidin, IFN-gamma, IL-4 and Th1/Th2 transcription factors in young healthy females. Eur. J. Clin. Nutr. 2014, 68(3):338-343.
27. Ohsawa M., Koyama T., Yamamoto K., Hirosawa S., Kamei S., Kamiyama R. 1alpha,25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation 2000, 102:2867-2872.
28. Chen Y., Kong J., Sun T., Li G., Szeto F.L., Liu W., Deb D.K., Wang Y., Zhao Q., Thadhani R., Li Y.C. 1,25-Dihydroxyvitamin D(3) suppresses inflammation-induced expression of plasminogen activator inhibitor-1 by blocking nuclear factor-kappaB activation. Archives Biochem. Biophysics 2011, 507:241-247.
29. Brondum-Jacobsen P., Benn M., Jensen G.B., Nordestgaard B.G. 25-hydroxyvitamin d levels and risk of ischemic heart disease, myocardial infarction, and early death: population-based study and meta-analyses of 18 and 17 studies. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2794-2802.
30. Ding C., Gao D., Wilding J., Trayhurn P., Bing C. Vitamin D signalling in adipose tissue. Br. J. Nutr. 2012, 108:1915-1923.
31. Bland R., Markovic D., Hills C.E., Hughes S.V., Chan S.L., Squires P.E., Hewison M. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J.Steroid Biochem. Mol. Biol. 2004, 89-90:121-125.
32. Reusch J.E., Begum N., Sussman K.E., Draznin B. Regulation of GLUT-4 phosphorylation by intracellular calcium in adipocytes. Endocrinology 1991, 129:3269-3273.
33. 2+ concentration in pancreatic beta-cells through nongenomic signal transduction. Endocrinology 1999, 140:4706-4712.
34. Dunlop T.W., Vaisanen S., Frank C., Molnar F., Sinkkonen L., Carlberg C. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. J.Mol. Biol. 2005, 349:248-260.
35. Wolden-Kirk H., Rondas D., Bugliani M., Korf H., Van Lommel L., Brusgaard K., Christesen H.T., Schuit F., Proost P., Masini M., Marchetti P., Eizirik D.L., Mathieu O.C. Discovery of molecular pathways mediating 1,25-dihydroxyvitamin D protection against cytokine-induced inflammation and damage of human and male mouse islets of langerhans. Endocrinology 2014, 155(3):736-747. en20131409.
36. Chiu K.C., Chu A., Go V.L., Saad M.F. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am. J. Clin. Nutr. 2004, 79:820-825.
37. Pittas A.G., Harris S.S., Stark P.C., Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 2007, 30:980-986.
38. Pittas A.G., Chung M., Trikalinos T., Mitri J., Brendel M., Patel K., Lichtenstein A.H., Lau J., Balk E.M. Systematic review: vitamin D and cardiometabolic outcomes. Ann. Intern Med. 2010, 152:307-314.
39. Afzal S., Brondum-Jacobsen P., Bojesen S.E., Nordestgaard B.G. Vitamin D concentration, obesity, and risk of diabetes: a mendelian randomisation study. Lancet. Diabetes Endocrinol. 2014, 2:298-306.
40. Talmor-Barkan Y., Bernheim J., Green J., Benchetrit S., Rashid G. Calcitriol counteracts endothelial cell pro-inflammatory processes in a chronic kidney disease-like environment. J.Steroid Biochem. Mol. Biol. 2011, 124:19-24.
41. Pilz S., Tomaschitz A., Drechsler C., Ritz E., Boehm B.O., Grammer T.B., Marz W. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur. Heart J. 2010, 31:1591-1598.
42. Elamin M.B., Abu Elnour N.O., Elamin K.B., Fatourechi M.M., Alkatib A.A., Almandoz J.P., Liu H., Lane M.A., Mullan R.J., Hazem A., Erwin P.J., Hensrud D.D., Murad M.H., Montori V.M. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J.Clin. Endocrinol. Metab. 2011, 96:1931-1942.
43. Kunutsor S.K., Burgess S., Munroe P.B., Khan H. Vitamin D and high blood pressure: causal association or epiphenomenon?. Eur. J. Epidemiol. 2014, 29(1):1-14.
44. Jaimungal S., Wehmeier K., Mooradian A.D., Haas M.J. The emerging evidence for vitamin D-mediated regulation of apolipoprotein A-I synthesis. Nutr. Res. 2011, 31:805-812.
45. Wang J.H., Keisala T., Solakivi T., Minasyan A., Kalueff A.V., Tuohimaa P. Serum cholesterol and expression of ApoAI, LXRbeta and SREBP2 in vitamin D receptor knock-out mice. J.Steroid Biochem. Mol. Biol. 2009, 113:222-226.
46. Wehmeier K.R., Mazza A., Hachem S., Ligaray K., Mooradian A.D., Wong N.C., Haas M.J. Differential regulation of apolipoprotein A-I gene expression by vitamin D receptor modulators. Biochim. Biophys. Acta 2008, 1780:264-273.
47. Ponda M.P., Huang X., Odeh M.A., Breslow J.L., Kaufman H.W. Vitamin D may not improve lipid levels: a serial clinical laboratory data study. Circulation 2012, 126:270-277.
48. Moura F.A., Dutra-Rodrigues M.S., Cassol A.S., Parra E.S., Zago V.H., Panzoldo N.B., Alexandre F., Vieira I.C., Vendrame F., Virginio V.W., Castanho V.S., Danelon M.R., Nunes V.S., Leanca C.C., Saraiva F.K., Coelho O.R., Nakandakare E., Quintao E.C., de Faria E.C., Sposito A.C. Impact of seasonality on the prevalence of dyslipidemia: a large population study. Chronobiology Int. 2013, 30:1011-1015.
49. Institute_of_Medicine Dietary References Intakes for Calcium and Vitamin D 2010, National Academies Press, Washington, DC.
50. Enko D., Fridrich L., Rezanka E., Stolba R., Ernst J., Wendler I., Daniel F., Hauptlorenz S., Halwachs-Baumann G. 25-hydroxy-vitamin D status: limitations in comparison and clinical interpretation of serum-levels across different assay methods. Clin. Lab. 2014, 60:1541-1550.
51. Farrell C.J., Martin S., McWhinney B., Straub I., Williams P., Herrmann M. State-of-the-art vitamin D assays: a comparison of automated immunoassays with liquid chromatography-tandem mass spectrometry methods. Clin. Chem. 2012, 58:531-542.
52. Lai J.K., Lucas R.M., Clements M.S., Harrison S.L., Banks E. Assessing vitamin D status: pitfalls for the unwary. Mol. Nutr. food Res. 2010, 54:1062-1071.
53. Glendenning P., Taranto M., Noble J.M., Musk A.A., Hammond C., Goldswain P.R., Fraser W.D., Vasikaran S.D. Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays. Ann. Clin. Biochem. 2006, 43:23-30.
54. Carter G.D., Carter C.R., Gunter E., Jones J., Jones G., Makin H.L., Sufi S. Measurement of vitamin D metabolites: an international perspective on methodology and clinical interpretation. J.Steroid Biochem. Mol. Biol. 2004, 89-90:467-471.
55. Messenger W., Nielson C.M., Li H., Beer T., Barrett-Connor E., Stone K., Shannon J. Serum and dietary vitamin D and cardiovascular disease risk in elderly men: a prospective cohort study. Nutr. Metabolism, Cardiovasc. Dis. : NMCD 2012, 22:856-863.
56. Cawthon P.M., Parimi N., Barrett-Connor E., Laughlin G.A., Ensrud K.E., Hoffman A.R., Shikany J.M., Cauley J.A., Lane N.E., Bauer D.C., Orwoll E.S., Cummings S.R. G.Osteoporotic fractures in men research, serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men. J.Clin. Endocrinol. Metab. 2010, 95:4625-4634.
57. Tomson J., Emberson J., Hill M., Gordon A., Armitage J., Shipley M., Collins R., Clarke R. Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12,000 deaths. Eur. Heart J. 2013, 34:1365-1374.
58. Wielders J.P., Wijnberg F.A. Preanalytical stability of 25(OH)-vitamin D3 in human blood or serum at room temperature: solid as a rock. Clin. Chem. 2009, 55:1584-1585.
59. Hustad S., Eussen S., Midttun O., Ulvik A., van de Kant P.M., Morkrid L., Gislefoss R., Ueland P.M. Kinetic modeling of storage effects on biomarkers related to B vitamin status and one-carbon metabolism. Clin. Chem. 2012, 58:402-410.
60. Balasubramanian R., Mueller L., Kugler K., Hackl W., Pleyer L., Dehmer M., Graber A. The impact of storage effects in biobanks on biomarker discovery in systems biology studies. Biomarkers : Biochem. Indic. Expo. response, Susceptibility Chem. 2010, 15:677-683.
61. Hollis B.W. Editorial: the determination of circulating 25-hydroxyvitamin D: no easy task. J.Clin. Endocrinol. Metab. 2004, 89:3149-3151.
62. Bishop J.E., Collins E.D., Okamura W.H., Norman A.W. Profile of ligand specificity of the vitamin D binding protein for 1 alpha,25-dihydroxyvitamin D3 and its analogs. J.Bone Mineral Res. Off J. Am. Soc. Bone Mineral Res. 1994, 9:1277-1288.
63. Anderson J.L., May H.T., Horne B.D., Bair T.L., Hall N.L., Carlquist J.F., Lappe D.L., Muhlestein J.B., G.Intermountain Heart Collaborative Study Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am. J. Cardiol. 2010, 106:963-968.
64. Nemerovski C.W., Dorsch M.P., Simpson R.U., Bone H.G., Aaronson K.D., Bleske B.E. Vitamin D and cardiovascular disease. Pharmacotherapy 2009, 29:691-708.
65. Wang T.J., Pencina M.J., Booth S.L., Jacques P.F., Ingelsson E., Lanier K., Benjamin E.J., D'Agostino R.B., Wolf M., Vasan R.S. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
66. Alele J.D., Luttrell L.M., Hollis B.W., Luttrell D.K., Hunt K.J., Group V.S. Relationship between vitamin D status and incidence of vascular events in the veterans affairs diabetes trial. Atherosclerosis 2013, 228:502-507.
67. Grandi N.C., Breitling L.P., Brenner H. Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies. Prev. Med. 2010, 51:228-233.
68. Giovannucci E., Liu Y., Hollis B.W., Rimm E.B. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern Med. 2008, 168:1174-1180.
69. Melamed M.L., Michos E.D., Post W., Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern Med. 2008, 168:1629-1637.
70. Amrein K., Quraishi S.A., Litonjua A.A., Gibbons F.K., Pieber T.R., Camargo C.A., Giovannucci E., Christopher K.B. Evidence for a U-shaped relationship between pre-hospital vitamin D status and mortality: a cohort study. J.Clin. Endocrinol. Metab. 2014, 99(4):1461-1469. jc20133481.
71. Kuhn T., Kaaks R., Teucher B., Hirche F., Dierkes J., Weikert C., Katzke V., Boeing H., Stangl G.I., Buijsse B. Plasma 25-hydroxyvitamin D and its genetic determinants in relation to incident myocardial infarction and stroke in the European prospective investigation into cancer and nutrition (EPIC)-Germany study. PloS One 2013, 8:e69080.
72. Jorde R., Schirmer H., Wilsgaard T., Joakimsen R.M., Mathiesen E.B., Njolstad I., Lochen M.L., Figenschau Y., Berg J.P., Svartberg J., Grimnes G. Polymorphisms related to the serum 25-hydroxyvitamin D level and risk of myocardial infarction, diabetes, cancer and mortality. The Tromso Study. PloS One 2012, 7:e37295.
73. Levin G.P., Robinson-Cohen C., de Boer I.H., Houston D.K., Lohman K., Liu Y., Kritchevsky S.B., Cauley J.A., Tanaka T., Ferrucci L., Bandinelli S., Patel K.V., Hagstrom E., Michaelsson K., Melhus H., Wang T., Wolf M., Psaty B.M., Siscovick D., Kestenbaum B. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA 2012, 308:1898-1905.
74. Hsia J., Heiss G., Ren H., Allison M., Dolan N.C., Greenland P., Heckbert S.R., Johnson K.C., Manson J.E., Sidney S., Trevisan M., I.Women's Health Initiative Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007, 115:846-854.
75. Bolland M.J., Grey A., Gamble G.D., Reid I.R. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet. Diabetes & Endocrinol. 2014, 2:307-320.
76. Chonchol M., Kendrick J., Targher G. Extra-skeletal effects of vitamin D deficiency in chronic kidney disease. Ann. Med. 2011, 43:273-282.
77. Holick M.F. Vitamin D deficiency. N.Engl. J. Med. 2007, 357:266-281.
78. Park C.W., Oh Y.S., Shin Y.S., Kim C.M., Kim Y.S., Kim S.Y., Choi E.J., Chang Y.S., Bang B.K. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am. J. Kidney Dis. 1999, 33:73-81.
79. Thadhani R., Appelbaum E., Pritchett Y., Chang Y., Wenger J., Tamez H., Bhan I., Agarwal R., Zoccali C., Wanner C., Lloyd-Jones D., Cannata J., Thompson B.T., Andress D., Zhang W., Packham D., Singh B., Zehnder D., Shah A., Pachika A., Manning W.J., Solomon S.D. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012, 307:674-684.
80. Autier P., Boniol M., Pizot C., Mullie P. Vitamin D status and ill health: a systematic review. Lancet. Diabetes Endocrinol. 2014, 2:76-89.
81. Ross A.C., Manson J.E., Abrams S.A., Aloia J.F., Brannon P.M., Clinton S.K., Durazo-Arvizu R.A., Gallagher J.C., Gallo R.L., Jones G., Kovacs C.S., Mayne S.T., Rosen C.J., Shapses S.A. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J.Clin. Endocrinol. Metab. 2011, 96:53-58.
82. Shapses S.A., Manson J.E. Vitamin D and prevention of cardiovascular disease and diabetes: why the evidence falls short. Jama 2011, 305:2565-2566.
83. Ducloux R., Nobecourt E., Chevallier J.M., Ducloux H., Elian N., Altman J.J. Vitamin D deficiency before bariatric surgery: should supplement intake be routinely prescribed?. Obes. Surg. 2011, 21:556-560.
84. Van der Schueren B., Green N., Gorroochurn P., Teixeira J., Altiner S., Laferrere B. Low vitamin D in candidates for bariatric surgery: are the Americans better off than the French?. Obes. Surg. 2011, 21:948-949. author reply 950.
85. Pilz S., Dobnig H., Nijpels G., Heine R.J., Stehouwer C.D., Snijder M.B., van Dam R.M., Dekker J.M. Vitamin D and mortality in older men and women. Clin. Endocrinol. 2009, 71:666-672.
86. Virtanen J.K., Nurmi T., Voutilainen S., Mursu J., Tuomainen T.P. Association of serum 25-hydroxyvitamin D with the risk of death in a general older population in Finland. Eur. J. Nutr. 2011, 50:305-312.
87. Bolland M.J., Bacon C.J., Horne A.M., Mason B.H., Ames R.W., Wang T.K., Grey A.B., Gamble G.D., Reid I.R. Vitamin D insufficiency and health outcomes over 5 y in older women. Am. J. Clin. Nutr. 2010, 91:82-89.
88. Eaton C.B., Young A., Allison M.A., Robinson J., Martin L.W., Kuller L.H., Johnson K.C., Curb J.D., Van Horn L., McTiernan A., Liu S., Manson J.E. Prospective association of vitamin D concentrations with mortality in postmenopausal women: results from the Women's health initiative (WHI). Am. J. Clin. Nutr. 2011, 94:1471-1478.
89. Jassal S.K., Chonchol M., von Muhlen D., Smits G., Barrett-Connor E. Vitamin d, parathyroid hormone, and cardiovascular mortality in older adults: the rancho bernardo study. Am. J. Med. 2010, 123:1114-1120.
90. Semba R.D., Houston D.K., Bandinelli S., Sun K., Cherubini A., Cappola A.R., Guralnik J.M., Ferrucci L. Relationship of 25-hydroxyvitamin D with all-cause and cardiovascular disease mortality in older community-dwelling adults. Eur. J. Clin. Nutr. 2010, 64:203-209.
91. Marniemi J., Alanen E., Impivaara O., Seppanen R., Hakala P., Rajala T., Ronnemaa T. Dietary and serum vitamins and minerals as predictors of myocardial infarction and stroke in elderly subjects. Nutr. Metabolism Cardiovasc. Dis. NMCD 2005, 15:188-197.
92. Hutchinson M.S., Grimnes G., Joakimsen R.M., Figenschau Y., Jorde R. Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: the tromso study. Eur. J. endocrinology/European Fed. Endocr. Soc. 2010, 162:935-942.
93. Michaelsson K., Baron J.A., Snellman G., Gedeborg R., Byberg L., Sundstrom J., Berglund L., Arnlov J., Hellman P., Blomhoff R., Wolk A., Garmo H., Holmberg L., Melhus H. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am. J. Clin. Nutr. 2010, 92:841-848.
94. Kilkkinen A., Knekt P., Aro A., Rissanen H., Marniemi J., Heliovaara M., Impivaara O., Reunanen A. Vitamin D status and the risk of cardiovascular disease death. Am. J. Epidemiol. 2009, 170:1032-1039.
95. Ginde A.A., Mansbach J.M., Camargo C.A. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the third national health and nutrition examination survey. Arch. Intern Med. 2009, 169:384-390.